STOCK TITAN

Ambow Education sets Dec. 18 vote on two directors

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
DEF 14A

Rhea-AI Filing Summary

Ambow Education Holding Ltd. (AMBO) will hold its annual meeting on December 18, 2026, where shareholders are asked to elect Chairwoman and CEO Jin Huang and independent non-executive director Yanhui Ma as Class III directors for terms ending at the 2029 annual meeting or until successors are appointed and qualified. Other proposals are to ratify Guangdong Prouden CPAs GP as auditor for the fiscal year ending December 31, 2026, and hold advisory votes on named executive officer compensation and the frequency of future compensation votes. The board recommends voting “FOR” the director nominees.

Class C shares carry 10 votes each, compared with one vote per Class A share. Jin Huang beneficially owns 4,708,415 Class C shares; the ownership table reports her voting stake as 47.67%. 2025 total compensation was $192,000 for Jin Huang, $182,000 for Chiao-Ling Hsu and $60,000 for James Bartholomew.

Positive

  • None.

Negative

  • Minor pointClass C shares carry 10 votes each, concentrating control in management.

Filing Explained

At December 31, 2025, plans had 3.18 million shares available for future issuance, alongside 3.32 million securities to be issued upon exercise of outstanding awards.

Ambow reports that, as of December 31, 2025, its equity plans had 3.32 million securities to be issued upon exercise of outstanding options, warrants and rights, and 3.18 million shares available for future issuance.

The available pool is capacity, not current issuance; if additional shares are issued under these arrangements, the share count would rise and existing holders’ percentage ownership would fall, absent offsetting changes. The 2024 Plan also provides for its share reserve to increase by 15% of shares offered in each future registration closing during the next two fiscal years ending December 31, 2026; that provision adds conditional plan capacity, not a commitment to issue those shares.

Annual meeting date December 18, 2026 Annual shareholders meeting.
Votes per Class A share 1 vote Ordinary share voting rights.
Votes per Class C share 10 votes Ordinary share voting rights.
Class C shares beneficially owned 4,708,415 shares Jin Huang, as reported in the ownership table.
Reported voting stake 47.67% Jin Huang, as reported in the ownership table.
Jin Huang total compensation $192,000 Year ended December 31, 2025.
Chiao-Ling Hsu total compensation $182,000 Year ended December 31, 2025.
James Bartholomew total compensation $60,000 Year ended December 31, 2025.
dual-class voting structure technical
"The main effect of the dual-class voting structure is to vest our management team"
Class C Ordinary Shares technical
"Each Class C Ordinary Share is entitled to ten (10) votes"
American Depositary Shares technical
"American Depositary Shares are frequently referred to as “ADSs”"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
compensation actually paid financial
"the term “compensation actually paid” should not be read literally"
restricted stock units financial
"Restricted stock units may be granted under our Amended 2010 Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
share appreciation rights financial
"Share appreciation rights may be granted under our Amended 2010 Plan"
Share appreciation rights (SARs) are a type of employee award that gives the holder a cash payment or stock equal to the increase in a company's share price over a set period, without requiring the employee to buy shares. For investors, SARs are important because they create a potential future cash outflow or share dilution tied directly to stock performance—like a bonus that grows when the stock goes up—so they affect company cash needs and share count.
Name Total Compensation
Jin Huang $192,000
Chiao-Ling Hsu $182,000
James Bartholomew $60,000
Say-on-Pay Result Advisory vote to approve compensation paid to the named executive officers.
Key Proposals
  • Election of Jin Huang and Yanhui Ma as Class III directors for terms ending at the 2029 annual meeting or until successors are appointed and qualified.
  • Ratification of Guangdong Prouden CPAs GP as independent auditor for the fiscal year ending December 31, 2026.
  • Advisory vote on named executive officer compensation.
  • Advisory vote on the frequency of future advisory votes on named executive officer compensation.
  • Other business properly presented at the annual meeting or any adjournment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will AMBO shareholders vote on at the December 18, 2026 annual meeting?

Shareholders will vote on director elections, auditor ratification and two advisory compensation matters: whether to approve named executive officer compensation and how often future advisory compensation votes should occur. The board recommends voting “FOR” Jin Huang and Yanhui Ma.

What was AMBO’s 2025 executive compensation?

Ambow reported 2025 total compensation of $192,000 for Jin Huang, $182,000 for Chiao-Ling Hsu and $60,000 for James Bartholomew. Huang’s total included $42,000 in option awards; Hsu’s included $32,000 and Bartholomew’s $25,000.

How many votes do AMBO Class A and Class C shares carry?

Class A shares carry one vote and Class C shares carry ten votes. Jin Huang beneficially owns 4,708,415 Class C shares; the ownership table reports 47.67% of total votes for her.

How do AMBO’s 2025 executive stock options vest?

The stock options granted in 2025 vest 25% on the first anniversary of the grant date, with the remaining 75% vesting ratably over the subsequent three years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
DEF 14A false 0001494558 0001494558 2024-01-01 2024-12-31 0001494558 2025-01-01 2025-12-31 0001494558 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2025-01-01 2025-12-31 0001494558 ecd:NonPeoNeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2025-01-01 2025-12-31 0001494558 ecd:PeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2025-01-01 2025-12-31 0001494558 ecd:PeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2025-01-01 2025-12-31 0001494558 ecd:PeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2025-01-01 2025-12-31 0001494558 ecd:PeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2025-01-01 2025-12-31 0001494558 ecd:PeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2025-01-01 2025-12-31 0001494558 ecd:PeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2025-01-01 2025-12-31 0001494558 ecd:PeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2024-01-01 2024-12-31 0001494558 ecd:PeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2024-01-01 2024-12-31 0001494558 ecd:PeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2024-01-01 2024-12-31 0001494558 ecd:PeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2024-01-01 2024-12-31 0001494558 ecd:PeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2024-01-01 2024-12-31 0001494558 ecd:PeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2024-01-01 2024-12-31 0001494558 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2025-01-01 2025-12-31 0001494558 ecd:NonPeoNeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2025-01-01 2025-12-31 0001494558 ecd:NonPeoNeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2025-01-01 2025-12-31 0001494558 ecd:NonPeoNeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2025-01-01 2025-12-31 0001494558 ecd:NonPeoNeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2024-01-01 2024-12-31 0001494558 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2024-01-01 2024-12-31 0001494558 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2024-01-01 2024-12-31 0001494558 ecd:NonPeoNeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2024-01-01 2024-12-31 0001494558 ecd:NonPeoNeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2024-01-01 2024-12-31 0001494558 ecd:NonPeoNeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2024-01-01 2024-12-31 iso4217:USD

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_______________________________

SCHEDULE14A
(Rule 14a-101)

_______________________________

INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant

 

☒

Filed by a Party other than the Registrant

 

☐

Check the appropriate box:

☐

 

Preliminary Proxy Statement

☐

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒

 

Definitive Proxy Statement

☐

 

Definitive Additional Materials

☐

 

Soliciting Material Pursuant to §240.14a-12

AMBOW EDUCATION HOLDING LTD.
(Name of Registrant as Specified in Its Charter)

_________________________________________________________________
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒

 

No fee required.

☐

 

Fee paid previously with preliminary materials

☐

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

AMBOW EDUCATION HOLDING LTD.

10080 N. Wolfe Rd, Suite SW3-200, Cupertino, CA 95014

_______________________________

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
to be held on December 18, 2026

_______________________________

TO THE SHAREHOLDERS OF AMBOW EDUCATION HOLDING LTD.:

The Annual Meeting of the shareholders of Ambow Education Holding Ltd., a Cayman Islands company (the “Company”), will be held on December 18, 2026, at 10:00 a.m. Pacific Time, at 1249 F St, San Diego, CA 92101, for the following purposes:

1.      To elect Jin Huang and Yanhui Ma to serve on the Board of Directors of the Company as a Class III director until the 2029 annual meeting of shareholders of the Company or until his or her respective successor is duly appointed and qualified (Proposal 1);

2.      To ratify the appointment of Guangdong Prouden CPAs GP as the independent auditor of the Company for the fiscal year ending December 31, 2026 relating to financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) (Proposal 2);

3.      To conduct an advisory vote for the approval of the compensation paid to the Company’s named executive officers (Proposal 3);

4.      To conduct an advisory vote on the frequency of future advisory votes on the compensation paid to the Company’s named executive officers (Proposal 4); and

5.      To transact any other business as may properly be presented at the Annual Meeting or any adjournment thereof.

A proxy statement, providing information, and a form of proxy to vote, with respect to the foregoing matters accompany this notice.

By Order of the Board of Directors,

   

/s/ Jin Huang

   

Jin Huang

   

Chairwoman of the Board

   

Dated: November 19, 2026

   

Important Notice Regarding Availability of Proxy Materials for the Shareholders Meeting
To Be Held on December 18, 2026.

The Proxy Statement and the Company’s annual report to Shareholders are available at the Company’s website, www.ambow.com.

 

IMPORTANT

Whether or not you expect to attend the Annual Meeting, please complete, date, and sign the accompanying proxy, and return it promptly in the enclosed return envelope. If you grant a proxy, you may revoke it at any time prior to the Annual Meeting, vote a subsequent proxy, or vote in person at the Annual Meeting.

PLEASE NOTE: If your shares are held in street name, your broker, bank, custodian, or other nominee holder cannot vote your shares in the election of directors (Proposal 1), or with respect to Proposal 3 or 4, unless you direct the nominee holder how to vote, by marking your proxy card.

 

AMBOW EDUCATION HOLDING LTD.

10080 N. Wolfe Rd, Suite SW3-200, Cupertino, CA 95014

_______________________________

PROXY STATEMENT
for
Annual Meeting of Shareholders
to be held on December 18, 2026

PROXY SOLICITATION

Ambow Education Holding Ltd., a Cayman Islands company (the “Company”) is soliciting proxies on behalf of the Board of Directors of the Company (the “Board”) in connection with the annual meeting of shareholders on December 18, 2026 and at any adjournment thereof. The Company will bear the entire cost of preparing, assembling, printing and mailing this Proxy Statement, the accompanying proxy, and any additional material that may be furnished to shareholders. Proxies also may be solicited through the mails or direct communication with certain shareholders or their representatives by the Company’s officers, directors, or employees, who will receive no additional compensation therefor.

November 19, 2026 is the approximate date on which this Proxy Statement and the accompanying form of proxy are first being sent to shareholders.

GENERAL INFORMATION ABOUT VOTING

Record Date, Outstanding Shares, and Voting Rights

As of November 13, 2026, the record date for the meeting, the Company had outstanding 57,127,524 ordinary shares, par value $0.003 per share (the “Ordinary Shares”) being the class of stock entitled to vote at the meeting, consisting of 52,419,109 Class A ordinary shares issued and outstanding and 4,708,415 Class C ordinary shares issued and outstanding. On all matters subject to vote at general meetings of the Company, the holders of Class A ordinary shares are entitled to one vote per share and the holders of Class C ordinary shares are entitled to ten votes per share. For us to hold a valid Annual Meeting, we must have a quorum, which means that greater than 33.33% of all Class A and Class C ordinary shares entitled to vote at the Annual Meeting must be present in person or by proxy. On the Record Date, there were 57,127,524 ordinary shares outstanding. Therefore, at least 19,040,604 shares need to be present in person or by proxy at the Annual Meeting in order to hold the meeting and conduct business.

Procedures for Voting or Revoking Proxies

You may vote your proxy by completing, dating, signing, and mailing the accompanying form of proxy in the return envelope provided. The persons authorized by any of those means to vote your shares will vote them as you specify or, in absence of your specification, as stated on the form of proxy. Abstentions and broker non-votes represented by submitted proxies will be included in the calculation of the number of the shares present at the Annual Meeting for the purposes of determining a quorum. “Broker non-votes” means shares held of record by a broker that are not voted because the broker has not received voting instructions from the beneficial owner of the shares and either lacks or declines to exercise the authority to vote the shares in its discretion. You may revoke any proxy by notifying the Company in writing at the above address, ATTN: Secretary, or by voting a subsequent proxy or in person at the meeting.

Proposal 1. The affirmative vote of a simple majority of the Class A and Class C ordinary shares (voting together) present and entitled to vote at the Annual Meeting is required for the election of each director. Proposal 1 is considered a “non-routine” matter under the applicable exchange rules, and, accordingly, brokerage firms and nominees do not have the authority to vote their clients’ unvoted shares on Proposal 1 or to vote their clients’ shares if the clients have not furnished voting instructions within a specified period of time prior to the Annual Meeting. Abstentions will be counted as shares present and entitled to vote and will have the same effect as a vote “against” Proposal 1. Broker non-votes will not be counted as shares entitled to vote on Proposal 1 and will have no effect on the outcome of the vote.

1

Proposal 2. The affirmative vote of a simple majority of the Class A and Class C ordinary shares (voting together) present and entitled to vote at the Annual Meeting is required for the ratification of the appointment of Guangdong Prouden CPAs GP as the independent auditor of the Company for the fiscal year ending December 31, 2026. Proposal 2 is considered a “routine” matter under the applicable exchange rules, and, accordingly, brokerage firms and nominees have the authority to vote their clients’ unvoted shares on Proposal 2 as well as to vote their clients’ shares where the clients have not furnished voting instructions within a specified period of time prior to the Annual Meeting. As a result, we do not expect any broker non-votes on Proposal 2. Abstentions will be counted as shares present and entitled to vote and will have the same effect as a vote “against” Proposal 2.

Proposal 3. To be approved, the proposal regarding the Company’s executive compensation for the fiscal year ended December 31, 2025 must receive the affirmative vote of a simple majority of the Class A and Class C ordinary shares (voting together) present and entitled to vote at the Annual Meeting. Proposal 3 is considered a “non-routine” matter under the applicable exchange rules, and, accordingly, brokerage firms and nominees do not have the authority to vote their clients’ unvoted shares on Proposal 3 or to vote their clients’ shares if the clients have not furnished voting instructions within a specified period of time prior to the Annual Meeting. Abstentions will be counted as shares present and entitled to vote and will have the same effect as a vote “against” Proposal 3. Broker non-votes will not be counted as shares entitled to vote on Proposal 3 and will have no effect on the outcome of the vote. The vote on Proposal 3 is advisory and therefore not binding on the Company, the Compensation Committee or the Board of Directors. Although non-binding, the Board of Directors values the opinions that the shareholders express in their votes, and the votes will provide information to the Compensation Committee regarding investor sentiment about the Company’s executive compensation philosophy, policies and practices, which the Compensation Committee will be able to consider when determining executive compensation in the future.

Proposal 4. The frequency (every one, two or three years) receiving the greatest number of votes cast will be considered the frequency selected by shareholders. Proposal 4 is considered a “non-routine” matter under applicable exchange rules, and, accordingly, brokerage firms and nominees do not have the authority to vote their clients’ unvoted shares on Proposal 4. Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the vote on Proposal 4. The vote on Proposal 4 is advisory and therefore not binding on the Company, the Compensation Committee or the Board of Directors.

Attending the Meeting

You may obtain directions to the meeting at www.ambow.com or by writing to the Company at the above address, ATTN: Secretary. If you attend the meeting, you may vote there in person, regardless of whether you have voted by any of the other means mentioned in the preceding paragraph.

2

SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding beneficial ownership of Ordinary Shares, as of the record date of the meeting, by each of the Company’s directors and executive officers; all executive officers and directors as a group, and each person known to the Company to own beneficially more than 5% of Company’s Ordinary Shares. Except as otherwise noted, the persons identified have sole voting and investment powers with respect to their shares.

As of November 13, 2026, the percentage of beneficial ownership for holders of Class A ordinary shares is based on 52,419,109 Class A ordinary shares issued and outstanding and the percentage of beneficial ownership for holders of Class C ordinary shares is based on 4,708,415 Class C ordinary shares issued and outstanding, both of which classes of ordinary shares exclude unvested restricted shares. On all matters subject to vote at general meetings of the Company, the holders of Class A ordinary shares are entitled to one vote per share and the holders of Class C ordinary shares are entitled to ten votes per share.

Citibank, N.A., the depositary, has advised us that, as of November 13, 2026, 894,529 ADSs, representing 17,890,588 underlying Class A ordinary shares were outstanding. The number of beneficial owners of our ADRs in the United States is likely to be much larger than the number of record holders of our Class A ordinary shares in the United States.

Unless otherwise indicated, the address of such individual is c/o Ambow Education Holding Ltd., 10080 N. Wolfe Rd., Suite SW3-200, Cupertino, CA 95014.

Name

 

Shares beneficially owned(1)

 

Percentage of votes held

Number of
Class A
ordinary
shares

 

Percentage
of Class A
Ordinary
shares
(%)

 

Number
of Class C
Ordinary
shares

 

Percentage
of Class C
ordinary
shares
(%)

 

Number
of total
ordinary
shares

 

Percentage
of total
ordinary
shares
(%)

 

Based
on total
Class A
ordinary
shares
(%)

 

Based
on total
Class C
ordinary
shares
(%)

 

Based
on Total
Ordinary
shares
(%)

Directors and Executive Officers:

       

 

       

 

       

 

   

 

   

 

   

 

Jin Huang(2)(5)

 

351,312

 

0.67

%

 

4,708,415

 

100

%

 

5,059,727

 

8.86

%

 

0.67

%

 

100

%

 

47.67

%

Yigong Justin Chen

 

—

 

—

 

 

—

 

—

 

 

—

 

—

 

 

—

 

 

—

 

 

—

 

Mingjun Wang

 

—

 

—

 

 

—

 

—

 

 

—

 

—

 

 

—

 

 

—

 

 

—

 

Yanhui Ma

 

—

 

—

 

 

—

 

—

 

 

—

 

—

 

 

—

 

 

—

 

 

—

 

Chiao-Ling Hsu

 

—

 

—

 

 

—

 

—

 

 

—

 

—

 

 

—

 

 

—

 

 

—

 

James Bartholomew

 

—

 

—

 

 

—

 

—

 

 

—

 

—

 

 

—

 

 

—

 

 

—

 

All executive officers and directors of the Company as a group (6 persons)(4)

 

1,138,430

 

2.17

%

 

4,708,415

 

100

%

 

5,846,845

 

10.23

%

 

2.17

%

 

100

%

 

48.46

%

5% and Greater Shareholders

       

 

       

 

       

 

   

 

   

 

   

 

New Summit Global Limited

 

2,703,475

 

5.16

%

 

—

 

—

 

 

2,703,475

 

4.73

%

 

5.16

%

 

—

 

 

2.72

%

CEIHL Partners (I) Limited(3)

 

3,420,375

 

6.53

%

 

—

 

—

 

 

3,420,375

 

5.99

%

 

6.53

%

 

—

 

 

3.44

%

CEIHL Partners (II) Limited(3)

 

11,144,636

 

21.26

%

 

—

 

—

 

 

11,144,636

 

19.51

%

 

21.26

%

 

—

 

 

11.20

%

New Flourish Holdings Limited(5)(6)

 

770,212

 

1.47

%

 

4,288,415

 

91.08

%

 

5,058,627

 

8.85

%

 

1.47

%

 

91.08

%

 

43.87

%

Spin-Rich Ltd.(5)(7)

 

—

 

—

 

 

420,000

 

8.92

%

 

420,000

 

0.74

%

 

—

 

 

8.92

%

 

4.22

%

____________

Note: Shares of executive officers and directors less than 1% of outstanding shares and shares of shareholders less than 5% of outstanding shares were not shown.

(1)      In computing the number of shares beneficially owned by a person and the percentage ownership of a person, shares subject to warrants or other derivative securities held by that person that are currently exercisable or exercisable within 60 days are deemed outstanding. Such shares, however, are not deemed outstanding for purposes of computing the percentage ownership of each other person. Except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares.

3

(2)      Of the 351,312 Class A Ordinary Shares (i) 287,214 of the Class A Ordinary Shares are owned by New Flourish Holdings Limited (“New Flourish”) for the benefit of Dr. Huang and certain officers of the Company, and (ii) 64,098 of the Class A Ordinary Shares are owned directly by Dr. Huang. Dr. Huang as the sole director of New Flourish has voting control and investment power over the Class A Ordinary Shares held by New Flourish, but disclaims beneficial ownership over such shares, which are held for the benefit of certain officers of the Company.

(3)      Mrs. Ye Wen is the sole shareholder of CEIHL Partners (I) Limited and CEIHL Partners (II) Limited (collectively “CEIHL”). CEIHL Partners (I) Limited holds 3,420,375 Class A Ordinary Shares and CEIHL Partners (II) Limited holds 11,144,636 Class A Ordinary Shares. As the sole shareholder of CEIHL Partners (I) Limited and CEIHL Partners (II) Limited, Mrs. Ye Wen has sole voting and dispositive power over the Class A Ordinary Shares held by CEIHL.

(4)      Includes Class A Ordinary Shares and Class C Ordinary Shares held by all of our directors and executive officers as a group.

(5)      Of the 4,708,415 Class C Ordinary Shares, (i) 4,288,415 of the Class C Ordinary Shares are owned by New Flourish for the benefit of Dr. Jin Huang, and (ii) 420,000 of the Class C Ordinary Shares are owned by Spin-Rich Ltd. Dr. Huang as the sole director of New Flourish has voting control and investment power over the Class C Ordinary Shares held by New Flourish.

(6)      Dr. Jin Huang, as the sole director of New Flourish has voting control and investment power over the Class A Ordinary Shares and the Class C Ordinary Shares owned by New Flourish. Dr. Huang disclaims beneficial ownership over the Class A Ordinary Shares held by New Flourish, which are held for the benefit of certain officers of the Company.

(7)      Dr. Jin Huang has sole voting control and investment power over Class C Ordinary Shares owned by Spin-Rich Ltd.

Except as disclosed in this proxy statement, there are no relationships between the parties, other than the voting proxies given to Dr. Jin Huang and the contractual control arrangements disclosed in this proxy statement. We are not aware of any relationship or arrangement between or among any shareholders that would enable any of them to control, in substance or contractually, any other shareholder’s vote.

Description of Securities

As of the record date of this meeting, we had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act:

Title of each class

 

Trading
symbol(s)

 

Name of each exchange
on which registered

American depositary shares (one American depositary share representing twenty Class A Ordinary Shares, par value $0.003 per share) **

 

AMBO

 

NYSE American LLC

Class A Ordinary Shares, par value $0.003 per share*

     

NYSE American LLC

____________

*        Not for trading, but only in connection with the listing on the NYSE American.

**      Effective on February 20, 2024, the ratio of ADSs to our Class A Ordinary Shares was changed from one ADS representing two Class A Ordinary Shares to one ADS representing twenty Class A Ordinary Shares.

This section contains a description of the rights of (i) holders of share(s) and (ii) holders of ADS(s). Shares underlying the ADSs are held by Citibank, N.A., as depositary, and holders of ADSs will not be treated as holders of the shares.

As of the record date of this meeting, our authorized share capital is US$230,000 divided into 66,666,667 Class A Ordinary Shares with a par value of US$0.003 per Class A Ordinary Share, 8,333,333 Class C Ordinary Shares with a par value of US$0.003 per Class C Ordinary Share, and 1,666,667 undesignated preferred shares with a par value of US$0.003 per preferred share. As of the record date of this meeting, there were 52,419,109 Class A Ordinary Shares and 4,708,415 Class C Ordinary Shares issued and outstanding.

In connection with the proposal to adopt the Sixth Amended and Restated Memorandum and Articles of Association, in our current report on Form 6-K filed on June 4, 2015, we sought approval to, among other things, create a new class of ordinary shares entitled Class C Ordinary Shares (“Class C Shares”), which were in addition to the Class A Ordinary Shares which had already been designated. The Class C Shares would be entitled to ten (10) votes on all matters subject to vote at our general meetings. On November 8, 2015, 4,708,415 of the Class A Ordinary Shares held by Dr. Jin Huang were exchanged for 4,708,415 Class C Shares. This exchange was approved by all disinterested members of the Board of Directors. The Class C shares were created with the intention to issue such shares to our management. The main effect of the dual-class voting structure is to vest our management team, especially Dr. Jin Huang, with significant control over Ambow’s decisions, allowing

4

management the freedom to focus on the long term by ensuring that it retained control over Ambow. The structure would also prevent outside parties from taking over or unduly influencing management decisions. As such, investors would fully share in our long term economic future, but would have less ability to influence strategic decisions through their voting rights.

All of our outstanding ordinary shares are fully paid and non-assessable. Certificates representing the ordinary shares are issued in registered form. The ordinary shares are not entitled to any preemptive conversion, subscription or redemption rights. Our shareholders may freely hold and vote their shares. Each Class A Ordinary Share is entitled to one vote and each Class C Ordinary Share is entitled to ten votes on all matters upon which the ordinary shares are entitled to vote, including the election of directors. Voting at any meeting of shareholders is by a poll.

Any ordinary resolution to be made by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast in person or by proxy at a meeting of our shareholders. A special resolution requires the affirmative vote of not less than two-thirds of the votes cast in person, by a duly authorized representative in the case of a shareholder who is a corporation, or by proxy at a meeting of our shareholders or a unanimous written resolution of all our shareholders. A special resolution is required for matters such as removing an independent director for cause, changing our name, amending our Sixth Amended and Restated Memorandum and Articles of Association and reducing our authorized share capital.

Each Class C Ordinary Share is convertible into one Class A Ordinary Share at any time by the holder thereof. Class A Ordinary Shares are not convertible under any circumstances. If at any time Jin Huang, our Chairwoman and Chief Executive Officer, and her affiliates collectively own less than 5% of the total number of the issued and outstanding Class C Ordinary Shares, each issued and outstanding Class C Ordinary Share shall be automatically and immediately converted into one share of Class A Ordinary Shares without payment of additional consideration and no Class C Ordinary Shares shall thereafter be issuable by us.

Pursuant to our Sixth Amended and Restated Memorandum and Articles of Association, our Board of Directors has the authority, without further action by the shareholders, to issue up to 1,666,667 preferred shares in one or more series and determine the designations, powers, preferences, privileges and other rights, including dividend rights, conversion rights, redemption rights and liquidation preferences, any or all of which may be greater than the rights of the ordinary shares. Subject to the directors’ duty of acting for a proper purpose, preferred shares can be issued quickly with terms calculated to delay or prevent a change of control of our company or make removal of management more difficult. Additionally, the issuance of preferred shares may have the effect of decreasing the market price of our ordinary shares and may adversely affect the voting and other rights of the holders of ordinary shares. As of the record date of this meeting, no such preferred shares have been issued, and we have no present plans to issue any such preferred shares.

American Depositary Shares

Citibank, N.A. is the depositary bank for our American Depositary Shares. Citibank’s depositary offices are located at 388 Greenwich Street, New York, New York 10013. American Depositary Shares are frequently referred to as “ADSs” and represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as “American Depositary Receipts” or “ADRs.” The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A. — Hong Kong, located at 10/F, Harbour Front (II), 22 Tak Fung Street, Hung Hom, Kowloon, Hong Kong.

Each ADS represents the right to receive twenty Class A Ordinary Shares, par value $0.003 per share, on deposit with the custodian. An ADS also represents the right to receive any other property received by the depositary or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations.

As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the Class A Ordinary Shares represented by your ADSs. See “Description of shares and governing documents — Ordinary shares — Voting rights” of the Company’s Annual Report on Form 10-K filed with the SEC on February 13, 2026 for a description of the voting rights of holders of ordinary shares.

5

At our request, the depositary will distribute to you any notice of shareholders’ meeting received from us together with information explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to holders of ADSs instructions on how to retrieve such materials upon request.

Voting at our shareholder meetings is by poll. If the depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder’s ADSs in accordance with such voting instructions.

Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. Securities for which no voting instructions have been received will not be voted.

Securities Authorized for Issuance under Equity Compensation Plans

As of December 31, 2025, our 2010 and 2024 Equity Incentive Plans were in effect.

The following table sets forth certain information about the securities authorized for issuance under our incentive plans as of December 31, 2025:

Plan Category

 

(a)

 

(b)

 

(c)

Number of securities
to be issued upon
exercise of outstanding
options, warrants and
rights

 

Weighted-
average
exercise price of
outstanding
options,
warrants and
rights

 

Number of securities
remaining available
for future issuance
under equity
compensation
plan (excluding
securities
reflected in column

Equity compensation plan approved by shareholders

 

3,320,000

 

$

0.13

 

3,180,000

Equity compensation plans not approved by shareholders

 

—

 

 

—

 

—

Total

 

3,320,000

 

$

0.13

 

3,180,000

6

PROPOSAL 1

ELECTION OF DIRECTORS

Nominees of the Board of Directors

Our Board of Directors currently consists of four directors: Dr. Jin Huang, Mr. Justin Chen, Dr. Yanhui Ma and Mr. Mingjun Wang.

We have a staggered board. The directors are divided into Class I, Class II and Class III, respectively. All of our directors are elected for three year terms.

No shareholder has the contractual right to designate persons to be elected to our Board of Directors, and our Sixth Amended and Restated Memorandum and Articles of Association provides that directors will be elected upon a resolution passed at a duly convened shareholders meeting by holders of a majority of our outstanding shares being entitled to vote in person or by proxy at such meeting, to hold office until the expiration of their respective terms. There is no minimum shareholding or age limit requirement for qualification to serve as a member of our Board of Directors.

The Board of Directors, upon the recommendation of the Corporate Governance and Nominating Committee, has nominated the persons identified under the caption Class III for election as a director, to serve until the 2029 annual meeting or until his or her respective successor is duly appointed and qualified. If any nominee becomes unavailable for election, which is not expected, the persons named in the accompanying proxy intend to vote for any substitute whom the Board of Directors nominates.

Class III

 

Class II

 

Class I

Jin Huang

 

Mingjun Wang(1)(2)

 

Yigong Justin Chen(1)

Yanhui Ma(1)(2)

       

____________

(1)      Member of the Audit Committee

(2)      Member of the Compensation Committee

The Company has no reason to believe that the nominees will not be a candidate or will be unable to serve. However, in the event that any nominee should become unable or unwilling to serve as a director, the persons named in the proxy have advised that they will vote for the election of such person or persons as shall be designated by the directors.

If a quorum is present at the Annual Meeting, each Class III nominee for director receiving the affirmative vote of a simple majority of the shares present and entitled to vote in person or by proxy for the election of directors at the Annual Meeting will be elected to our Board of Directors.

The following sets forth certain information with respect to our directors.

Yigong Justin Chen has served as a member of our board of directors since March 2013. Mr. Justin Chen is an independent non-executive director of the Company. Mr. Chen is a counsel at PacGate Law Group. He is a California licensed attorney and is qualified to practice before the United States Patent and Trademark Office. Mr. Chen graduated from the University of Iowa, College of Law in 1998, with a Juris Doctor degree and graduated from Peking University, Department of Biochemistry with a bachelor’s degree in 1992 and obtained his Master of Biochemistry and Juris Doctor degrees, both from University of Iowa in 1995 and 1998, respectively.

Mingjun Wang has served as a member of our board of directors since September 2022 and is an independent non-executive director of the Company. Mr. Mingjun Wang, has over 30 years of operating and management experience in the education and publishing industries. Since 2003, he has served as Chairman of the board of directors of Beijing Century Oriental Science and Technology Inc. Since 2017, he has been an executive partner of Edtech Venture, a U. S. venture capital firm. Mr. Wang is also an entrepreneur and independent investor in the United States and China, with investment portfolios including Splashtop, Homatch, Century Oriental, OSA Technologies, 100E Inc. etc. Previously, Mr. Wang held Editor In Chief and Vice President positions of the Publishing House of Electronics Industry of China, and served as a member of the board of directors of China Electronics Association. Mr. Wang joined Pearson Education as international rights manager in 1999.

7

Mr. Wang graduated from Stanford University, School of Business in 1998 with a Master of Science in Management degree, obtained his Master of Electronics Engineering degree from Xidian University in 1988 and a Bachelor of Science degree from Shandong University, Department of Mathematics in 1983.

Jin Huang has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in August 2000, and has served as our Acting Chief Financial Officer since September 2022. Dr. Huang has over 15 years of academic and industry experience in Silicon Valley. Prior to founding Ambow, Dr. Huang was a founding engineer at Avant!, where she was responsible for product design and engineering management. Dr. Huang holds a bachelor’s degree in Computer Science, a master’s degree in Computer Science and a Ph.D. in Electronic Engineering from the University of Electronic Science & Technology of China. From 1990 to 1993, Dr. Huang was doing research and completed her Ph.D. dissertation at the University of California, Berkeley.

Yanhui Ma joined the board of directors in May 2014. Dr. Ma is an independent non-executive director of the Company. Dr. Ma has been involved in the creation, funding and development of several healthcare companies, especially joint venture corporations between China and the United States. Dr. Ma also served on the board of directors of several healthcare related corporations he founded or co-founded in the US and China, including Sinocare and SinoMed. Dr. Ma organized and co-founded the International Drug Delivery Society and served as Vice Chairman of the Society previously. He also served as the Vice President of US Silicon Valley Chinese Business Association.

The business address of each of our directors is c/o Ambow Education Holding Ltd., 10080 N. Wolfe Rd, Suite SW3-200, Cupertino, CA 95014.

There are no family relationships among any of our directors and executive officers. None of our non-executive directors has any employment or service contract with the Company. We believe that each of the non-executive members of our Board of Directors is an “independent director” as that term is used in the NYSE corporate governance rules.

Term of Office

We have a staggered Board. The Directors are divided into Class I, Class II and Class III, respectively and are assigned to each class in accordance with a resolution or resolutions adopted by the Board of Directors.

•        At the first annual general meeting of Members (a person whose name is entered in the Register of Members as the holder of a share or shares) following the initial meeting, the term of office of the Class I Directors shall expire and Class I Directors shall be elected for a full term of three years.

•        At the second annual general meeting of Members following the initial meeting, the term of office of the Class II Directors shall expire and Class II Directors shall be elected for a full term of three years.

•        At the third annual general meeting of Members following the initial meeting, the term of office of the Class III Directors shall expire and Class III Directors shall be elected for a full term of three years.

•        At each succeeding annual general meeting of Members, Directors shall be elected for a full term of three years to succeed the Directors of the class whose terms expire at such annual general meeting.

The following table sets forth the names and classes of our directors as of the date of the record date of this meeting:

Class I

 

Class II

 

Class III

Yigong Justin Chen

 

Mingjun Wang

 

Jin Huang

       

Yanhui Ma

A director may be removed for negligence or other reasonable cause at any time before the expiration of his or her term by a special resolution passed at a duly convened shareholder meeting by the holders of at least two-thirds of our outstanding shares being entitled to vote in person or by proxy at such meeting or by unanimous written consent of our shareholders. Vacancies on our Board of Directors created by such a removal or by resignation may be filled by resolution passed at a duly convened shareholder meeting by the holders of a majority of our outstanding

8

shares entitled to vote in person or by proxy at such meeting or by a majority vote of the remaining directors in office. A director so elected or appointed shall hold office until the next succeeding annual shareholder meeting and may be nominated for reelection at that time.

Board Practice

As of December 31, 2025, our Board of Directors consisted of four directors:

Dr. Jin Huang, Mr. Justin Chen, Mr. Mingjun Wang and Dr. Yanhui Ma. Our directors are elected for three-year terms.

We believe that each of the non-executive members of our Board of Directors is an “independent director” as that term is used in the NYSE corporate governance rules.

No shareholder has the contractual right to designate persons to be elected to our Board of Directors, and our Sixth Amended and Restated Memorandum and Articles of Association provides that directors will be elected upon a resolution passed at a duly convened shareholders meeting by holders of a majority of our outstanding shares being entitled to vote in person or by proxy at such meeting, to hold office until the expiration of their respective terms. There is no minimum shareholding or age limit requirement for qualification to serve as a member of our Board of Directors.

A director may vote on a proposal, arrangement or contract in which the director is interested, provided that such director has disclosed his interest in such matter to the Board of Directors at a meeting of the Board of Directors.

In addition, our Board of Directors may exercise all the powers of the Company to borrow money, mortgage or charge its undertaking, property and uncalled capital, and issue debentures, debenture stock and other securities whenever money is borrowed or as a security for any debt, liability or obligation of the Company or of any third party.

The Board’s Role in Risk Oversight

One person holds the positions of principal executive officer and chairman of the Board of Directors of the Company. The Board of Directors has not designated a lead director. Given the limited number of directors comprising the Board, the independent directors call and plan their executive sessions collaboratively and, between board meetings, communicate with management and one another directly. In the circumstances, the directors believe that formalizing in a lead director functions in which they all participate might detract from rather than enhance performance of their responsibilities as directors. The Chairwoman of the Board chairs the board and shareholder meetings and participates in preparing their agendas. The Chairwoman of the Board of Directors also serves as a focal point for communication between management and the Board of Directors between Board meetings, although there is no restriction on communication between directors and management. The Company believes that these arrangements afford the directors sufficient resources to supervise management effectively, without being overly engaged in day-to-day operations.

The Company’s business and affairs are managed under the direction of the Board of Directors. The Board of Directors consists of four directors, including three independent directors, namely Mr. Justin Chen, Mr. Mingjun Wang and Dr. Yanhui Ma. A director is not required to hold any shares in the Company to qualify as a director.

The Board of Directors has extensive involvement in the oversight of risk management related to the Company and its business and will accomplish this oversight through the regular reporting to the Board of Directors by the audit committee. The audit committee represents the Board by periodically reviewing the Company’s accounting, reporting and financial practices, including the integrity of its financial statements, the surveillance of administrative and financial controls and its compliance with legal and regulatory requirements. Through its regular meetings with management, including the finance, legal, internal audit and information technology functions, the audit committee reviews and discusses all significant areas of the Company’s business and summarize for the Board of Directors all areas of risk and the appropriate mitigating factors. In addition, the Board of Directors receives periodic detailed operating performance reviews from management.

9

Board Meetings and Committees

Our Board of Directors holds meetings as circumstances require. In addition to regularly scheduled Board meetings, the independent directors of the Board meet on a regular basis to fulfill their responsibilities on each of the Board committees. The independent directors also meet annually in executive sessions without the presence of management and non-independent directors.

The Board of Directors held three meetings during 2025. During our last fiscal year, each of our directors attended at least 75% of the aggregate of (i) the total number of Board meetings and (ii) the total number of meetings of the committees on which the director served.

Independent Directors

NYSE American rules generally require that independent directors must comprise a majority of a listed company’s board of directors. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, the Company has determined that Mr. Justin Chen, Mr. Mingjun Wang and Dr. Yanhui Ma, representing three of the Company’s four directors, are “independent” as that term is used in the NYSE corporate governance rules and applicable SEC rules.

Duties of directors

In general, under Cayman Islands law, our directors have a duty of loyalty to act honestly, in good faith and in our best interests. Our directors also have a duty to exercise the care, diligence and skills that a reasonably prudent person would exercise in comparable circumstances. In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association then in effect. In certain limited circumstances, our shareholders have the right to seek damages through a derivative action in the name of the Company if a duty owed by our directors is breached.

Committees of the Board of Directors

The Board of Directors has established an audit committee, a compensation committee and a corporate governance and nominating committee, which have the responsibilities and authority necessary to comply with applicable NYSE American and SEC rules. The Board may from time to time establish other committees.

The Company’s chief executive officer and other executive officers will regularly report to the non-executive directors and the audit, compensation, corporate governance and nominating committees to ensure effective and efficient oversight of the Company’s activities and to assist in proper risk management and the ongoing evaluation of management controls. We believe that the leadership structure of the Board will provide appropriate risk oversight of the Company’s activities.

Audit Committee

Our audit committee consists of Yigong Justin Chen, Mingjun Wang and Yanhui Ma, each of whom meets the independence standards of the NYSE and the SEC. Yigong Justin Chen is the Chairperson of our audit committee. Dr. Yanhui Ma serves as our audit committee financial expert. The responsibilities of our audit committee include, among other things:

•        Appointing and overseeing the work of our independent auditors, approving the compensation of our independent auditors, and, if appropriate, discharging our independent auditors;

•        Pre-approving engagements of our independent auditors to render audit services and/or establishing pre-approval policies and procedures for such engagements and pre-approving any non-audit services proposed to be provided to us by our independent auditors;

•        Discussing with management and our independent auditors significant financial reporting issues raised and judgments made in connection with the preparation of our financial statements;

10

•        Reviewing and discussing reports from our independent auditors on (1) the major critical accounting policies to be used, (2) significant alternative treatments of financial information within the U.S. generally accepted accounting principles, or GAAP, that have been discussed with management, (3) ramifications of the use of such alternative disclosures and treatments, and (4) other material written communications between our independent auditors and management;

•        Resolving any disagreements between management and our independent auditors regarding financial reporting;

•        Establishing procedures for receiving, retaining and treating any complaints we receive regarding accounting, internal accounting controls or auditing matters and procedures for the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and

•        Reporting regularly to the full Board of Directors.

During 2025, the audit committee held one meeting.

Audit Committee Report

With respect to the audit of the Company’s financial statements for the year ended December 31, 2025, the Audit Committee:

•        reviewed and discussed the audited financial statements with management;

•        discussed with the Company’s independent accountants the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board and the SEC; and

•        received the written disclosures and the letter from the independent accountant required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant’s communications with the Audit Committee concerning independence and has discussed with the independent accountant the independent accountant’s independence.

Based upon the foregoing review and discussion, the Audit Committee recommended to the Board that the audited financial statements be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on February 13, 2026.

Yigong Justin Chen, Chair
Mingjun Wang
Yanhui Ma

Compensation Committee

Our compensation committee consists of Yanhui Ma and Mingjun Wang, each of whom is an “independent director” as that term is used in the NYSE corporate governance rules. Mingjun Wang is the Chairperson of our compensation committee. Our compensation committee assists the Board of Directors in reviewing and approving the compensation structure of our directors and officers, including all forms of compensation to be provided to our directors and officers. The responsibilities of our compensation committee include, among other things:

•        Reviewing and recommending to our Board of Directors with respect to the total compensation package for our executive officers;

•        Reviewing and recommending to our Board of Directors with respect to director compensation, including equity-based compensation; and

•        Reviewing periodically and recommending to the Board of Directors with respect to any long-term incentive compensation or equity plans, programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.

During 2025, our compensation committee held two meetings.

11

Corporate governance and nominating committee

Our corporate governance and nominating committee consists of Yigong Justin Chen, Yanhui Ma and Mingjun Wang, each of whom is an “independent director” as that term is used in the NYSE corporate governance rules. Mingjun Wang is the Chairperson of our corporate governance and nominating committee. The corporate governance and nominating committee assists the Board of Directors in selecting individuals qualified to become our directors and in determining the composition of the Board and its committees. The corporate governance and nominating committee is responsible for, among other things:

•        identifying and recommending to the Board nominees for election to the Board or for appointment to fill any vacancy that is anticipated or has arisen on the Board;

•        reviewing annually with the Board the current composition of the Board in light of the characteristics of independence, age, skills, experience and availability of service to us of its members and of anticipated needs;

•        identifying and recommending to the Board the directors to serve as members of the Board’s committees;

•        advising the Board periodically regarding significant developments in law and practice of corporate governance and making recommendations to the Board on all matters of corporate governance;

•        monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance; and

•        reporting regularly to the entire Board of Directors.

Code of Ethics

Our Code of Conduct and Ethics, or Code, summarizes the ethical standards and key policies that guide our business conduct and applies to our directors, executive officers and employees. The purpose of the Code is to promote ethical conduct and deter wrongdoing. The policies outlined in the Code are designed to ensure that our directors, executive officers and employees act in accordance with not only the letter but also the spirit of the laws and regulations that apply to our business. We expect our directors, executive officers and employees to exercise good judgment, to uphold these standards in their day-to-day activities, and to comply with all applicable policies and procedures in the course of their relationship with the company. A copy of our Code is posted on our website at www.ambow.com. Our Code is a “code of ethics,” as defined in Item 406(b) of Regulation S-K. Please note that our Internet website address is provided as an inactive textual reference only. The Company will make any legally required disclosures regarding amendments to, or waivers of, provisions of its code of ethics on its Internet website. A printed copy of the Code of Ethics may be obtained free of charge by writing to us at our headquarters located at 10080 N. Wolfe Rd, Suite SW3-200, Cupertino, CA 95014 or on our website, www.ambow.com.

Insider Trading Policy

We have adopted insider trading policies and procedures, governing the purchase, sale, and other dispositions of the Company’s securities by directors, senior management, and employees that are reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing standards applicable to the Company. A copy of the Insider Trading Policy was filed as Exhibit 19 to our 2025 Form 10-K filed with the SEC on February 13, 2026.

12

Involvement in Certain Legal Proceedings

To the best of our knowledge, except as described below, none of our directors or executive officers has, during the past ten years:

•        been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences);

•        had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;

•        been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;

•        been found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

•        been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

•        been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Communication with our Board of Directors

Our shareholders and other interested parties may communicate with our Board of Directors by sending written communication in an envelope addressed to “Board of Directors” in care of the Chief Executive Officer, 10080 N. Wolfe Rd, Suite SW3-200, Cupertino, CA 95014, United States of America.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 requires our officers, directors and persons who own more than ten percent of a registered class of our equity securities to file reports of ownership and changes in ownership with the Securities and Exchange Commission. Officers, directors and ten percent shareholders are required by regulation to furnish us with copies of all Section 16(a) forms they file. Based solely on a review of such reports and written representations from our officers and directors, we believe that, during the fiscal year ended December 31, 2025, all Section 16(a) filing requirements applicable to our officers, directors and greater than ten percent beneficial owners were timely met.

13

Executive Compensation

Summary Compensation Table — Years Ended December 31, 2025 and 2024

The following table sets forth information concerning the compensation of our named executive officers for the years ended December 31, 2025 and 2024:

     

Salary

 

Bonus

 

Stock
Awards

 

Option
Awards

 

Non-Equity
Incentive
Plan
Compensation

 

Nonqualified
Deferred
compensation
earnings

 

Other
Compensation

 

Total

       

(In thousands)

Name and Principal Position

 

Year

 

($)

 

($)

 

($)

 

($)

 

($)

 

($)

 

($)

 

($)

Jin Huang,

 

12/31/25

 

$

150

 

$

—

 

$

—

 

$

42

 

$

—

 

$

—

 

$

—

 

$

192

Chief Executive Officer, Chairwoman of the Board and Director

 

12/31/24

 

$

150

 

$

—

 

$

—

 

 

—

 

$

—

 

$

—

 

$

—

 

$

150

       

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Chiao-Ling Hsu,

 

12/31/25

 

$

150

 

$

—

 

$

—

 

$

32

 

$

—

 

$

—

 

$

—

 

$

182

Chief Operating Officer, and President of NewSchool of Architecture & Design

 

12/31/24

 

$

150

 

$

—

 

$

—

 

$

—

 

$

—

 

$

—

 

$

—

 

$

150

       

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

James Bartholomew,

 

12/31/25

 

$

35

 

$

—

 

$

—

 

$

25

 

$

—

 

$

—

 

$

—

 

$

60

President(1)

 

12/31/24

 

$

—

 

$

—

 

$

—

 

$

—

 

$

—

 

$

—

 

$

—

 

$

—

____________

(1)      Mr. Bartholomew joined the Company in May 2025, and therefore did not receive compensation for a full fiscal year in 2025.

Employment Agreements

Service agreement with Dr. Jin Huang

We entered into a service agreement dated August 28, 2007 with Dr. Jin Huang, our Chief Executive Officer. The initial employment term under this service agreement was two years, automatically extending by successive periods of 12 months, unless we or Dr. Huang give the other party a written notice three months prior to the commencement of the next 12-month period indicating that the notifying party does not wish to extend the employment term, in which case the employment term will expire at the end of such three-month notice period.

In the event that we terminate Dr. Huang’s employment for cause, or if Dr. Huang voluntarily resigns (other than a resignation for good cause following a change of control), Dr. Huang will not be entitled to receive any severance benefits, provided that Dr. Huang will be able to exercise any vested and unexercised awards under our equity incentive plans in accordance with the terms set forth therein.

In the event that we terminate Dr. Huang’s employment under circumstances other than a change of control and for any reason other than for cause or voluntary termination, or if within 24 months after a change of control, Dr. Huang is involuntarily terminated (other than for cause) or voluntarily resigns for good cause, Dr. Huang will be entitled to certain severance benefits, including:

•        A lump sum payment consisting of: (i) an amount equal to one-time Dr. Huang’s then annual salary; (ii) a prorated bonus based on target opportunity for the year; and (iii) an amount equal to 12 months’ housing allowance;

•        The right to exercise any and all unexercised stock options granted under our equity incentive plans in accordance with their terms, as if all such unexercised stock options were fully vested, within one year of the effective date of such termination; and

•        Any other bonus amounts or benefits to which Dr. Huang may be entitled under any of our benefit plans.

14

Pursuant to the service contract, Dr. Huang also has agreed to certain non-competition undertakings during the term of her employment and for a period of one-year following any termination of her employment. These non-competition undertakings include that Dr. Huang may not, during the one-year period following any termination of her employment, (i) solicit or entice away any of our clients or prospective clients, (ii) have any business dealings with any of our clients or prospective clients, (iii) solicit or entice away any individual who is employed by us as a director or in a managerial, executive or technical capacity, or employ or engage any such individual, or (iv) carry on, set up, be employed, engaged or interested in a business anywhere in the PRC which is in competition with our business as of the termination date. These non-competition undertakings will not prohibit Dr. Huang from seeking or doing any business that is not in direct or indirect competition with our business, nor will they prevent Dr. Huang from holding shares or other capital not amounting to more than 5% of the total issued share capital of any company which is listed on a regulated market. Dr. Huang is entitled to receive one-half of her annual base salary over the post-termination non-competition period as consideration for her non-competition undertakings, which are subject to our making such payments.

“Cause” means that Dr. Huang habitually neglects her duties to us or engages in gross misconduct during the term of the service agreement and “gross misconduct” means her misappropriation of funds, securities fraud, insider trading, unauthorized possession of corporate property, the sale, distribution, possession or use of a controlled substance, conviction of any criminal offense or entry of a plea of nolo contendere (or similar plea) to a charge of such an offense or a breach of the service agreement and failure to cure such breach within ten days after written notice thereof.

“Good cause” means, without Dr. Huang’s express prior written consent, (i) she is assigned duties materially inconsistent with her position, duties, responsibilities, or status with the Company which substantially vary from that which existed immediately prior to the change of control, and such reassignment is not directly related to her incapacity, disability or any “cause”; (ii) she experiences a change in her reporting levels, titles, or business location (more than 50 miles from her current business location or residence, whichever is closer to the new business location) which substantially varies from that which existed immediately prior to the change of control, and such change is not directly related to her incapacity, disability or any “cause”; (iii) she is removed from any position held immediately prior to the change of control, or if she fails to obtain reelection to any position held immediately prior to the change of control, which removal or failure to reelect is not directly related to her incapacity or disability, “cause” or death; (iv) she experiences a reduction in salary of more than ten percent below that which existed immediately prior to the change of control, and such reduction is not directly related to her incapacity, disability or any “cause”; (v) she experiences an elimination or reduction of any employee benefit, business expenses, reimbursement or allotment, incentive bonus program, or any other manner or form of compensation available to her immediately prior to the change of control and such change is not otherwise applied to others in the Company with her position or title and is not directly related to her incapacity, disability or any “cause”; or (vi) we fail to obtain from any successor, before the succession takes place, a written commitment obligating the successor to perform the service agreement in accordance with all of its terms and conditions.

“Change of control” means (i) any merger, consolidation, or sale of the Company such that any individual, entity or group acquires beneficial ownership of 50 percent or more of our voting capital stock, (ii) any transaction in which we sell substantially all of our material assets, (iii) our dissolution or liquidation, (iv) any change in the control of the composition of our Board of Directors such that the shareholders who as of the date of the service agreement controlled the composition of our Board of Directors shall cease to have such control, or (v) there has occurred a “change of control,” as such term (or any term of like import) is defined in any of the following documents which is in effect with respect to us at the time in question: any note, evidence of indebtedness or agreement to lend funds to us, any option, incentive or employee benefit plan of us or any employment, severance, termination or similar agreement with any person who is then our employee.

Employment Agreements with our other Executive Officers

We have entered into employment agreements with most of our executive officers. Under these agreements, most of our executive officers are employed for a specified time period subject to renewal. As stipulated under the applicable laws, we may be required to provide severance compensation as expressly required by applicable law. In certain cases, in the event of termination without cause, we are also required to provide severance compensation in accordance with the terms of the applicable employment agreement.

15

Confidential information and invention assignment agreements

We have also entered into a confidential information and invention assignment agreement with each of our executive officers. We require all of our employees to execute the same confidential information and invention assignment agreement or an agreement on substantially similar terms. Under the terms of the agreement, each executive officer has agreed to hold, both during and after such executive officer’s term of employment, in strictest confidence and not to use, except for our benefit, or to disclose to any person, firm or corporation without written authorization, any confidential information. Confidential information does not include any information that has become publicly known and made generally available through no wrongful act of our executive officers. Each executive officer has also agreed during such officer’s term of employment not to improperly use or disclose any proprietary information or trade secrets of any former or current employer or other person or entity unless consented to in writing by such employer, person or entity. In addition, each executive officer has agreed to disclose to us, hold in trust for the sole right and benefit of us and assign to us, all right, title and interest in and to, any and all inventions, original works of authorship, developments, concepts, improvements or trade secrets, whether or not patentable or registerable under copyright or similar laws, which such executive officer may solely or jointly conceive, develop or reduce to practice or cause to be conceived, developed or reduced to practice, during the period of employment. Furthermore, each executive officer has agreed to not directly or indirectly solicit, induce, recruit or encourage any employees to leave their employment during the twelve-month period immediately following such executive officer’s termination of employment.

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth, for each named executive officer, information regarding unexercised stock options, unvested stock awards, and equity incentive plan awards outstanding as of December 31, 2025.

 

OUTSTANDING EQUITY AWARDS AT 2025 FISCAL YEAR END

   

OPTION AWARDS

 

STOCK AWARDS

Name

 

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

 

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

 

Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)

 

Option
Exercise
Price
($)

 

Option
Expiration
Date

 

Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)

 

Market
Value of
Shares or
Units of
Stock
That
Have Not
Vested
($)

 

Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested
(#)

 

Equity
Incentive
Plan
Awards:
Market
or Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That
Have Not
Vested
($)

Jin Huang,

 

—

 

400,000.00

 

—

 

$

0.13

 

3/27/2035

 

—

 

—

 

—

 

—

CEO and Acting CFO

             

 

                     
               

 

                     

Chiao-Ling Hsu,

 

—

 

300,000.00

 

—

 

$

0.13

 

3/27/2035

 

—

 

—

 

—

 

—

COO and President of NewSchool of Architecture & Design

             

 

                     
               

 

                     

James Bartholomew,

 

—

 

200,000.00

 

—

 

$

0.16

 

5/13/2035

 

—

 

—

 

—

 

—

President

             

 

                     

Compensation Committee Interlocks and Insider Participation

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Pension Benefits

None of Ambow’s named executive officers participate in or have account balances in qualified or nonqualified defined benefit plans sponsored by it.

16

Nonqualified Deferred Compensation

None of Ambow’s named executive officers participate in or have account balances in nonqualified defined contribution plans or other deferred compensation plans maintained by it.

Director Compensation

We primarily use monthly fees and stock option grants to attract and retain qualified candidates to serve on the Board. This compensation reflected the financial condition of the Company. In setting director compensation, we consider the significant amount of time that directors expend in fulfilling their duties to the Company as well as the skill-level required by our members of the Board. During the year ended December 31, 2025, Dr. Jin Huang did not receive any compensation for her services as director. The compensation disclosed in the “Summary Compensation Table” above represents the total compensation for Dr. Jin Huang.

Our independent non-employee directors are compensated in stock option grants. There is no formal stock compensation plan for independent non-employee directors. Our non-employee directors received the following compensation during the year ended December 31, 2025:

 

Fees
Earned or
Paid in
Cash

 

Stock
Awards

 

Option
Awards

 

Non-equity
Incentive
Plan
Compensation

 

Nonqualified
Deferred
Compensation
Earnings

 

Other
Compensation

 

Total

   

(In thousands)

Name

 

($)

 

($)

 

($)

 

($)

 

($)

 

($)

 

($)

Yanhui Ma

 

$

—

 

—

 

$

21

 

—

 

—

 

—

 

$

21

Yigong Justin Chen

 

$

—

 

—

 

$

21

 

—

 

—

 

—

 

$

21

Mingjun Wang

 

$

—

 

—

 

$

32

 

—

 

—

 

—

 

$

32

Potential payments upon termination or change-in-control

Other than the severance and change-of-control benefits provided under Dr. Jin Huang’s service agreement described above under “Employment Agreements,” and any severance required by applicable law or the terms of an executive officer’s employment agreement, we do not have change-in-control agreements with any of our directors or executive officers and are not obligated to pay severance or other enhanced benefits to executive officers upon termination of their employment.

Recovery of Erroneously Awarded Compensation

None.

Policies and Practices for Granting Certain Equity Awards

Our policies and practices regarding the granting of equity awards are carefully designed to ensure compliance with applicable securities laws and to maintain the integrity of our executive compensation program. The Compensation Committee is responsible for the timing and terms of equity awards to executives and other eligible employees.

The timing of equity award grants is determined with consideration to a variety of factors, including but not limited to, the achievement of pre-established performance targets, market conditions and internal milestones. The Company does not follow a predetermined schedule for the granting of equity awards; instead, each grant is considered on a case-by-case basis to align with the Company’s strategic objectives and to ensure the competitiveness of our compensation packages.

In determining the timing and terms of an equity award, the Board or the Compensation Committee may consider material nonpublic information to ensure that such grants are made in compliance with applicable laws and regulations. The Board’s or the Compensation Committee’s procedures to prevent the improper use of material nonpublic information in connection with the granting of equity awards include oversight by legal counsel and, where appropriate, delaying the grant of equity awards until the public disclosure of such material nonpublic information.

17

The Company is committed to maintaining transparency in its executive compensation practices and to making equity awards in a manner that is not influenced by the timing of the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. The Company regularly reviews its policies and practices related to equity awards to ensure they meet the evolving standards of corporate governance and continue to serve the best interests of the Company and its shareholders.

Pay Versus Performance

The following pay versus performance disclosure is required by rules adopted by the SEC in the fall of 2022. The disclosure required for smaller reporting companies consists of a Pay Versus Performance table and reconciliation of the information reported in the table. The SEC believes this disclosure will help shareholders better evaluate the link between executive pay and performance, both for the Company on a stand-alone basis and as compared to other publicly traded companies.

The Pay Versus Performance table is highly regulated and requires pay disclosure that is intended to supplement what we customarily provide in the Summary Compensation Table and the other executive compensation tables. The table currently provides SEC mandated compensation data for fiscal years 2024 and 2025 for our Named Executive Officers (“NEOs”), including our principal Executive Officer (“PEO”), along with certain financial performance measures. In reviewing the table, our shareholders should note the following:

•        The amounts in columns (b) and (d) of the table are taken from or derived directly from the total compensation paid to the relevant NEOs as reported in the current year or prior year Summary Compensation Tables;

•        The “compensation actually paid” in columns (c) and (e) represents an additional type of compensation disclosure mandated by the SEC, the intent of which is to try and isolate the amount of compensation earned by the relevant NEO(s) in each year. To calculate “compensation actually paid,” we are required to start with the totals for that year as reported in the Summary Compensation Table, deduct the Summary Compensation Table values for stock and option awards, and then add back amounts for new and previously outstanding stock and option awards in a manner mandated by the SEC. The disclosure and calculations are complex and can be confusing, and the amounts determined in accordance with the rules often bear no relation to the money or the economic value received or monetized by a particular NEO in the given year. We therefore caution that the term “compensation actually paid” should not be read literally and does not actually reflect the “take home” amounts received by our NEOs in a given year; and

•        The SEC rules require that we include in the Pay Versus Performance table information regarding our U.S. GAAP net income results. U.S. GAAP net income was not a performance metric in any of our compensation programs and did not affect the compensation awarded to our NEOs for the years covered by the Pay Versus Performance Table. We are nonetheless required to include such information in the table, and we urge our investors to keep in mind that U.S. GAAP net income did not drive the amount of pay awarded to or realized by our NEOs.

Pay Versus Performance Table

(a)

 

(b)

 

(c)

 

(d)

 

(e)

 

(f)

 

(g)

Fiscal Year

 

Summary
Compensation
Table Total
for PEO

 

Compensation
Actually
Paid to
PEO
(1)

 

Average
Summary
Compensation
Table Total
for Non-PEO
NEOs

 

Average
Compensation
Actually paid
to Non-PEO
NEOs
(1)

 

Value of
Initial
Fixed $100
Investment
Based on
Total
Shareholder
Return
(2)

 

Net Income
available
to Ambow
Common
Shareholder
(in thousands)

2025

 

$

192,000

 

$

192,760

 

$

121,000

 

$

119,225

 

$

200

 

$

1,359

2024

 

$

150,000

 

$

150,000

 

$

150,000

 

$

150,000

 

$

152

 

$

309

18

____________

To calculate the amounts reported in the “Compensation Actually Paid” columns in the table above, the following amounts were deducted from and added to (as applicable) the total compensation of our PEO and the average total compensation of our non-PEO NEOs as reported in the Summary Compensation Table (“SCT”) for the fiscal years ended December 31, 2025 and 2024:

(1)      Our PEO for each year presented was Jin Huang, our Chief Executive Officer and Acting Chief Financial Officer. Our non-PEO NEO for 2024 was Chiao-Ling Hsu, and our non-PEO NEOs for 2025 were Chiao-Ling Hsu and James Bartholomew. To calculate compensation actually paid, adjustments were made to the amounts reported in the Summary Compensation Table for the applicable year, as described in the reconciliation table below.

(2)      Pursuant to rules of the SEC, the illustration assumes $100 was invested on December 31, 2023 in our Ordinary Shares. Historic common share price performance is not necessarily indicative of future common share price performance.

To calculate the amounts reported in the “Compensation Actually Paid” columns in the table above, the following amounts were deducted from and added to (as applicable) our NEOs total compensation as reported in the Summary Compensation Table (“SCT”) for our named executive officers as of December 31, 2025:

         

Less:

 

Plus:

 

Plus (less):

   
       

(a)

 

(b)

 

(c)

 

(d)

 

(e)

 

(f)

 

(g)

   

Name

 

Fiscal
Year

 

SCT
Total

 

SCT
Option
Awards

 

Year-End
Fair
Value of
Equity
Awards
Granted
in the
Covered
Year and
Unvested at
Year-End

 

Change in
Fair
Value of
Unvested
Equity
Awards
Granted
in Prior
Years

 

Fair
Value of
Equity
Awards
Granted
and
Vested
in the
Covered
Year

 

Change in
Fair
Value of
Prior-Year
Equity
Awards
that
Vested
in the
Covered
Year

 

Fair
Value of
Prior-Year
Equity
Awards
Forfeited
in the
Covered
Year

 

Compensation
Actually
Paid

Jin Huang

 

2025

 

$

192,000

 

$

(42,000

)

 

$

42,760

 

$

—

 

$

—

 

$

—

 

$

—

 

$

192,760

(Principal Executive Officer and Principal Financial Officer)

 

2024

 

$

150,000

 

$

—

 

 

$

—

 

$

—

 

$

—

 

$

—

 

$

—

 

$

150,000

       

 

   

 

 

 

 

 

   

 

   

 

   

 

   

 

   

 

 

Average for Non-PEO

 

2025

 

$

121,000

 

$

(28,500

)

 

$

26,725

 

 

—

 

 

—

 

 

—

 

 

—

 

$

119,225

NEOs

 

2024

 

$

150,000

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

$

150,000

____________

(a)      Represents Total Compensation as reported in the Summary Compensation Table for the indicated fiscal year.

(b)      Represents the grant date fair value of the option awards granted during the indicated fiscal year, as reported in the SCT, computed in accordance with the methodology used for financial reporting purposes. No equity awards were granted to the PEO or non-PEO NEOs in fiscal 2024.

(c)      Represents the fair value as of December 31, 2025 of the outstanding and unvested stock options granted during fiscal 2025 (400,000 options to Dr. Huang, 300,000 options to Ms. Hsu and 200,000 options to Mr. Bartholomew), computed in accordance with the methodology used for financial reporting purposes.

(d)      Represents the change in fair value during the indicated fiscal year of each RSU that was granted in a prior fiscal year and that remained outstanding and unvested as of the last day of the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.

(e)      No equity awards were granted and vested to the PEO or non-PEO NEOs during fiscal 2025 or 2024. The stock options granted in 2025 vest 25% on the first anniversary of the grant date and the remaining 75% ratably over the subsequent three years.

(f)      Represents the change in fair value, measured from the prior fiscal year-end to the vesting date, of each RSU that was granted in a prior fiscal year and which vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.

(g)      Represents the average amount of change in fair value as of the end of the applicable year (from the end of the prior fiscal year) of equity awards granted in prior years that were unvested as of year-end of the applicable year.

Compensation of Directors

We primarily use monthly fees and stock option grants to attract and retain qualified candidates to serve on the Board. This compensation reflected the financial condition of the Company. In setting director compensation, we consider the significant amount of time that directors expend in fulfilling their duties to the Company as well as the skill-level required by our members of the Board. During the year ended December 31, 2025, Dr. Jin Huang did not receive any compensation for her services as director. The compensation disclosed in the “Summary Compensation Table” above represents the total compensation for Dr. Jin Huang.

19

Our independent non-employee directors are compensated in stock option grants. There is no formal stock compensation plan for independent non-employee directors. Our non-employee directors received the following compensation during the year ended December 31, 2025:

 

Fees
Earned or
Paid in
Cash

 

Stock
Awards

 

Option
Awards

 

Non-equity
Incentive
Plan
Compensation

 

Nonqualified
Deferred
Compensation
Earnings

 

Other
Compensation

 

Total

   

(In thousands)

Name

 

($)

 

($)

 

($)

 

($)

 

($)

 

($)

 

($)

Yanhui Ma

 

$

—

 

—

 

$

21

 

—

 

—

 

—

 

$

21

Yigong Justin Chen

 

$

—

 

—

 

$

21

 

—

 

—

 

—

 

$

21

Mingjun Wang

 

$

—

 

—

 

$

32

 

—

 

—

 

—

 

$

32

Equity-based compensation plans

2010 Equity Incentive Plan

On June 1, 2010, we adopted the 2010 Equity Incentive Plan, or the “2010 Plan,” which became effective upon the completion of our IPO on August 5, 2010, and terminated automatically 10 years after its adoption.

Amended and Restated 2010 Equity Incentive Plan

On December 21, 2018, we amended and restated the 2010 Plan, which became effective upon the approval of the shareholders at the Annual Meeting of Shareholders on December 21, 2018. The Amended 2010 Plan will continue in effect for 10 years from the date adopted by the Board, unless terminated earlier under section 18 of the Plan.

Share reserve.    The maximum aggregate number of our ordinary shares that may be issued under our Amended 2010 Plan is such number of shares as shall be equal to 6,500,000 Class A Ordinary Shares, plus any shares that subject to stock options or similar awards granted under the 2005 Stock Plan that expire or otherwise terminate without having been exercised in full, and shares issued pursuant to awards granted under the 2005 Stock Plan that are forfeited to or converted by the Company, with the maximum number of shares to be added to the Amended 2010 Plan equal to 293,059 Class A Ordinary Shares. In addition, our Amended 2010 Plan provides for increases in the number of shares available for issuance thereunder on the closing day of each future registration before the fiscal years ending December 31, 2020, in the amount equal to 15% of the Class A Ordinary Shares issued in each registration.

Shares issued pursuant to awards under the Amended 2010 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations related to an award, will become available for future grant under the Amended 2010 Plan. In addition, to the extent that an award is paid out in cash rather than shares, such cash payment will not reduce the number of shares available for issuance under the Amended 2010 Plan. As of December 31, 2023, the Company granted up to 7,305,222 Class A Ordinary Shares of the Company to its employees, outside directors and consultants.

Administration.    Our Board of Directors or a committee of our Board of Directors administers our Amended 2010 Plan. Different committees with respect to different groups of service providers may administer our Amended 2010 Plan. Subject to the provisions of our Amended 2010 Plan, the administrator has the power to determine the terms of the awards, including the recipients, the exercise price, the number of shares subject to each such award, the vesting schedule applicable to the awards, together with any vesting acceleration, and the form of consideration payable upon exercise. The administrator also has the authority to modify or amend awards, to prescribe rules and to construe and interpret the Amended 2010 Plan and to institute an exchange program whereby the exercise prices of outstanding awards may be reduced, outstanding awards may be surrendered in exchange for awards with a higher or lower exercise price, or outstanding awards may be transferred to a third party.

Options.    The administrator may grant incentive stock options (“ISOs”) or non-statutory stock options (“NSOs”) under our Amended 2010 Plan. The exercise price of options granted under our Amended 2010 Plan must at least be equal to the fair market value of our ordinary shares on the date of grant and its term may not exceed

20

10 years, except that with respect to any participant who owns more than 10% of the total combined voting power of all classes of our outstanding shares, or of certain of our parent or subsidiary corporations, the term of an ISO must not exceed five years and the exercise price of such ISO must equal at least 110% of the fair market value on the grant date. The administrator determines the term of all other options.

After termination of an employee, director or consultant, he or she may exercise his or her option, to the extent vested as of such date of termination, for the period of time stated in the option agreement. In the absence of a specified period of time in the option agreement, the option will remain exercisable for a period of three months following termination (or 12 months in the event of a termination due to death or disability). However, in no event may an option be exercised later than the expiration of its term.

Share appreciation rights.    Share appreciation rights may be granted under our Amended 2010 Plan. Share appreciation rights allow the recipient to receive the appreciation in the fair market value of our ordinary shares between the exercise date and the date of grant. The exercise price of share appreciation rights granted under our Amended 2010 Plan must at least be equal to the fair market value of our ordinary shares on the date of grant. The administrator determines the terms of share appreciation rights, including when such rights vest and become exercisable and whether to settle such awards in cash or with our ordinary shares, or a combination thereof. Share appreciation rights expire under the same rules that apply to options.

Restricted shares.    Restricted shares may be granted under our Amended 2010 Plan. Restricted share awards are ordinary shares that are subject to various restrictions, including restrictions on transferability and forfeiture provisions. Restricted shares will vest and the restrictions on such shares will lapse, in accordance with terms and conditions established by the administrator. The administrator will determine the number of restricted shares granted to any employee. The administrator may impose whatever conditions to vesting it determines to be appropriate. For example, the administrator may set restrictions based on the achievement of specific performance goals and/or continued service to us. Recipients of restricted share awards generally will have voting and dividend rights with respect to such shares upon grant without regard to vesting, unless the administrator provides otherwise. Restricted shares that do not vest for any reason will be forfeited by the recipient and will revert to us.

Restricted share units.    Restricted share units may be granted under our Amended 2010 Plan. Each restricted share unit granted is a bookkeeping entry representing an amount equal to the fair market value of an ordinary share. Restricted share units are similar to awards of restricted shares, but are not settled unless the award vests. The awards may be settled in shares, cash, or a combination of both, as the administrator may determine. The administrator determines the terms and conditions of restricted share units, including the vesting criteria and the form and timing of payment.

Performance units and performance shares.    Performance units and performance shares may be granted under our Amended 2010 Plan. Performance units and performance shares are awards that will result in a payment to a participant only if performance goals established by the administrator are achieved or the awards otherwise vest. The administrator will establish organizational or individual performance goals in its discretion, which, depending on the extent to which they are met, will determine the number and/or the value of performance units and performance shares to be paid out to participants. Performance units will have an initial dollar value established by the administrator prior to the grant date. Performance shares will have an initial value equal to the fair market value of our ordinary shares on the grant date. Payment for performance units and performance shares may be made in cash or in our ordinary shares with equivalent value, or in some combination, as determined by the administrator.

Transferability.    Unless the administrator provides otherwise, our Amended 2010 Plan does not allow for the transfer of awards other than by will or the laws of descent and distribution and only the recipient of an award may exercise an award during his or her lifetime.

Certain adjustments.    In the event of certain changes in our capitalization, to prevent diminution or enlargement of the benefits or potential benefits available under the Amended 2010 Plan, the administrator will make adjustments to one or more of the numbers and class of shares that may be delivered under the plan and/or the number, class and price of shares covered by each outstanding award and the numerical share limits contained in the plan. In the event of our proposed liquidation or dissolution, the administrator will notify participants as soon as practicable and all awards will terminate immediately prior to the consummation of such proposed transaction.

21

Change in control transactions.    Our Amended 2010 Plan provides that in the event of our merger or change in control, as defined in the Amended 2010 Plan, each outstanding award will be treated as the administrator determines, except that if the successor corporation or its parent or subsidiary does not assume or substitute an equivalent award for each outstanding award without the prior written consent of the participant, then such award will fully vest, all restrictions on such award will lapse, all performance goals or other vesting criteria applicable to such award will be deemed achieved at 100% of target levels and such award will become fully exercisable, if applicable, for a specified period prior to the transaction. The award will then terminate upon the expiration of the specified period of time.

Term, Amendment and Termination.    Our Amended 2010 Plan will become effective upon its adoption by the Board. It will continue in effect for a term of ten (10) years from the date adopted by the Board, unless terminated earlier under Section 18 of the Plan. Our Board of Directors has the authority to amend, suspend or terminate the 2010 Equity Incentive Plan, provided such action does not impair the rights of any participant with respect to any outstanding awards.

2024 Equity Incentive Plan

On December 20, 2024, we adopted the Company’s 2024 Equity Incentive Plan (the “Plan”), which became effective upon the approval of the shareholders at the Annual Meeting of Shareholders on December 20, 2024.

The 2024 Plan is a comprehensive incentive compensation plan under which we can grant equity-based and other incentive awards to our officers, employees, directors, consultants and advisers. The purpose of the Plan is to help us attract, motivate and retain such persons with awards under the Plan and thereby enhance shareholder value.

Administration.    The Plan is administered by the Board, and may be administered by the compensation committee of the Board, which shall consist of three members of the Board, each of whom is a “non-employee director” within the meaning of Rule 16b-3 promulgated under the Exchange Act and “independent” for purposes of any applicable listing requirements. If a member of the compensation committee is eligible to receive an award under the Plan, such compensation committee member shall have no authority under the plan with respect to his or her own award. Among other things, the compensation committee has complete discretion, subject to the express limits of the Plan, to determine the directors, employees and nonemployee consultants to be granted an award, the type of award to be granted the terms and conditions of the award, the form of payment to be made and/or the number of shares of common stock subject to each award, the exercise price of each option and base price of each stock appreciation right (“SAR”), the term of each award, the vesting schedule for an award, whether to accelerate vesting, the value of the common stock underlying the award, and the required withholding, if any. The compensation committee may amend, modify or terminate any outstanding award, provided that the participant’s consent to such action is required if the action would impair the participant’s rights or entitlements with respect to that award. The compensation committee is also authorized to construe the award agreements, and may prescribe rules relating to the Plan. Notwithstanding the foregoing, the compensation committee does not have any authority to grant or modify an award under the Plan with terms or conditions that would cause the grant, vesting or exercise thereof to be considered nonqualified “deferred compensation” subject to Code Section 409A, unless such award is structured to be exempt from or comply with all requirements of Code Section 409A.

Grant of Awards; Shares Available for Awards.    The Plan provides for the grant of stock options, SARs, performance share awards, performance unit awards, distribution equivalent right awards, restricted stock awards, restricted stock unit awards and unrestricted stock awards to non-employee directors, officers, employees and nonemployee consultants of Ambow Education Holding Ltd. or its affiliates. The maximum aggregate number of Shares that may be awarded and sold under the Plan is 6,500,000 ordinary shares. The number of ordinary shares available for issuance under the Plan shall automatically increase on the first trading day of January each calendar year during the term of the Plan, beginning with the calendar year 2025, resulting in the aggregate number of ordinary shares available under this Plan equaling fifteen percent (15%) of the total number of ordinary shares outstanding on the last trading day in December of the immediately preceding calendar year minus the total number of reserved and available shares under the Company’s 2005 Plan and 2010 Plan. No more than 6,500,000 shares of common stock in the aggregate may be issued under the Plan in connection with incentive stock options. Shares shall be deemed to have been issued under the Plan solely to the extent actually issued and delivered pursuant to

22

an award. If any award granted under the Plan expires, is canceled, or terminates unexercised or is forfeited, the number of shares subject thereto is again available for grant under the Plan. The Plan shall continue in effect, unless sooner terminated, until the tenth (10th) anniversary of the date on which it is adopted by the Board of Directors. The Board of Directors in its discretion may terminate the Plan at any time with respect to any shares for which awards have not theretofore been granted; provided, however, that the Plan’s termination shall not materially and adversely impair the rights of a holder, without the consent of the holder, with respect to any award previously granted.

Automatic Share Reserve Increase.    The number of Shares available for issuance under the Plan will be increased on the closing day of each future Registration (including closing of over-allotment options) during the next two fiscal years ending December 31, 2026, in an amount equal to fifteen percent (15%) of the Shares offered in each Registration.

Future new hires and additional non-employee directors and/or consultants would be eligible to participate in the Plan as well. The number of stock options and/or shares of restricted stock to be granted to executives and directors cannot be determined at this time as the grant of stock options and/or shares of restricted stock is dependent upon various factors such as hiring requirements and job performance.

Stock Options.    The Plan provides for either “incentive stock options” (“ISOs”), which are intended to meet the requirements for special federal income tax treatment under Section 422 of the Code, or “nonqualified stock options” (“NSOs”). Stock options may be granted on such terms and conditions as the compensation committee may determine, which shall be specified in the option agreement; provided, however, that the per share exercise price under a stock option may not be less than the fair market value of a share of common stock on the date of grant and the term of the stock option may not exceed 10 years (110% of such value and five years in the case of an ISO granted to an employee who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of capital stock of our Company or a parent or subsidiary of our Company). ISOs may only be granted to employees. In addition, the aggregate fair market value of common stock covered by one or more ISOs (determined at the time of grant), which are exercisable for the first time by an employee during any calendar year may not exceed $100,000. Any excess is treated as an NSO.

Stock Appreciation Rights.    A SAR entitles the participant, upon exercise, to receive an amount, in cash or stock or a combination thereof, equal to the increase in the fair market value of the underlying common stock between the date of grant and the date of exercise. The compensation committee shall set forth in the applicable SAR award agreement the terms and conditions of the SAR, including the base value for the SAR (which shall not be less than the fair market value of a share on the date of grant), the number of shares subject to the SAR and the period during which the SAR may be exercised and any other special rules and/or requirements which the compensation committee imposes on the SAR. No SAR shall be exercisable after the expiration of ten (10) years from the date of grant. SARs may be granted in tandem with, or independently of, stock options granted under the Plan. A SAR granted in tandem with a stock option (i) is exercisable only at such times, and to the extent, that the related stock option is exercisable in accordance with the procedure for exercise of the related stock option; (ii) terminates upon termination or exercise of the related stock option (likewise, the common stock option granted in tandem with a SAR terminates upon exercise of the SAR); (iii) is transferable only with the related stock option; and (iv) if the related stock option is an ISO, may be exercised only when the value of the stock subject to the stock option exceeds the exercise price of the stock option. A SAR that is not granted in tandem with a stock option is exercisable at such times as the compensation committee may specify.

Performance Shares and Performance Unit Awards.    Performance share and performance unit awards entitle the participant to receive cash or shares of common stock upon the attainment of specified performance goals. In the case of performance units, the right to acquire the units is denominated in cash values. The compensation committee shall set forth in the applicable award agreement the performance goals and objectives and the period of time to which such goals and objectives shall apply. If such goals and objectives are achieved, such distribution of shares, or payment in cash, as the case may be, shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar month next following the end of the Company’s fiscal year to which such performance goals and objectives relate, unless otherwise structured to comply with Code Section 409A.

Distribution Equivalent Right Awards.    A distribution equivalent right award entitles the participant to receive bookkeeping credits, cash payments and/or common stock distributions equal in amount to the distributions that would have been made to the participant had the participant held a specified number of shares of common

23

stock during the period the participant held the distribution equivalent right. A distribution equivalent right may be awarded as a component of another award (but not an option or SAR award) under the Plan, where, if so awarded, such distribution equivalent right will expire or be forfeited by the participant under the same conditions as under such other award. The compensation committee shall set forth in the applicable distribution equivalent rights award agreement the terms and conditions, if any, including whether the holder is to receive credits currently in cash, is to have such credits reinvested (at fair market value determined as of the date of reinvestment) in additional ordinary shares, or is to be entitled to choose among such alternatives.

Restricted Stock Awards.    A restricted stock award is a grant or sale of common stock to the holder, subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the compensation committee or the Board of Directors may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including based on achievement of performance goals and/or future service requirements), in such installments or otherwise, as the compensation committee or the Board of Directors may determine at the date of grant or purchase or thereafter. If provided for under the restricted stock award agreement, a participant who is granted or has purchased restricted stock shall have all of the rights of a shareholder, including the right to vote the restricted stock and the right to receive dividends thereon (subject to any mandatory reinvestment or other requirement imposed by the compensation committee or the Board of Directors or in the award agreement). During the restricted period applicable to the restricted stock, subject to certain exceptions, the restricted stock may not be sold, transferred, pledged, exchanged, hypothecated, or otherwise disposed of by the participant.

Restricted Stock Unit Awards.    A restricted stock unit award provides for a grant of shares or a cash payment to be made to the holder upon the satisfaction of predetermined individual service-related vesting requirements, based on the number of units awarded to the holder. The compensation committee shall set forth in the applicable restricted stock unit award agreement the individual service-based vesting requirements which the holder would be required to satisfy before the holder would become entitled to payment and the number of units awarded to the holder. The holder of a restricted stock unit shall be entitled to receive a cash payment equal to the fair market value of an ordinary share, or one ordinary share, as determined in the sole discretion of the compensation committee and as set forth in the restricted stock unit award agreement, for each restricted stock unit subject to such restricted stock unit award, if and to the extent the holder satisfies the applicable vesting requirements. Such payment or distribution shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar month next following the end of the calendar year in which the restricted stock unit first becomes vested, unless otherwise structured to comply with Code Section 409A. A restricted stock unit shall not constitute an equity interest in the Company and shall not entitle the Holder to voting rights, dividends or any other rights associated with ownership of Shares prior to the time the Holder shall receive a distribution of Shares

Unrestricted Stock Awards.    An unrestricted stock award is a grant or sale of shares of our common stock to the employees, non-employee directors or non-employee consultants that are not subject to transfer, forfeiture or other restrictions, in consideration for past services rendered to the Company or an affiliate or for other valid consideration.

Adjustments.    The aggregate number of shares of common stock reserved and available for issuance under the Plan, the individual limitations, the number of shares of common stock covered by each outstanding award, and the price per share of common stock underlying each outstanding award will be equitably and proportionally adjusted or substituted, as determined by the compensation committee in its sole discretion, as to the number, price or kind of stock or other consideration subject to such awards in connection with stock dividends, extraordinary cash dividends, stock splits, reverse stock splits, recapitalizations, reorganizations, mergers, amalgamations, consolidations, combinations, exchanges, or other relevant changes in our capitalization affecting our common stock or our capital structure which occurs after the date of grant of any award, in connection with any extraordinary dividend declared and paid in respect of stock or in the event of any change in applicable law or circumstances that results in or could result in, as determined by the compensation committee in its sole discretion, any substantial dilution or enlargement of the rights intended to be granted to, or available for, participants in the Plan.

Change-in-Control Provisions.    The compensation committee may, in its sole discretion, at the time an award is granted or at any time prior to, coincident with or after the time of a change in control, cause any award either (i) to be cancelled in consideration of a payment in cash or other consideration in amount per share equal to the excess, if any, of the price or implied price per share of common stock in the change in control over the per share exercise, base or purchase price of such award, which may be paid immediately or over the vesting schedule

24

of the award; (ii) to be assumed, or new rights substituted therefore, by the surviving corporation or a parent or subsidiary of such surviving corporation following such change in control; (iii) accelerate any time periods, or waive any other conditions, relating to the vesting, exercise, payment or distribution of an award so that any award to a holder whose employment has been terminated as a result of a change in control may be vested, exercised, paid or distributed in full on or before a date fixed by the compensation committee; (iv) to be purchased from a holder whose employment has been terminated as a result of a change of control, upon the holder’s request, for an amount of cash equal to the amount that could have been obtained upon the exercise, payment or distribution of such rights had such award been currently exercisable or payable; or (v) terminate any then outstanding award or make any other adjustment to the awards then outstanding as the compensation committee deems necessary or appropriate to reflect such transaction or change. The number of shares subject to any award shall be rounded to the nearest whole number.

Amendment and Termination.    The compensation committee may adopt, amend and rescind rules relating to the administration of the Plan, and amend, suspend or terminate the Plan, but no such amendment or termination will be made that materially and adversely impairs the rights of any participant with respect to any award received thereby under the Plan without the participant’s consent, other than amendments that are necessary to permit the granting of awards in compliance with applicable laws.

Certain Relationships and Related Transactions

Transactions with Related Persons

The following is a summary of transactions or series of transactions since January 1, 2024, or currently proposed transactions or series of transactions, to which we were, or will be, a party, in which the amount involved exceeded, or will exceed, $120,000, and in which any of our directors, executive officers, or to our knowledge, beneficial owners of 5% or more of our capital stock, or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest:

In January 2024, the Company borrowed $0.2 million from a member of the management team and fully repaid the borrowing by the end of March 2024.

Employment agreements

We have entered into a service contract with our Chief Executive Officer as well as employment agreements and confidential information and invention assignment agreements with each of our executive officers. See “Executive Compensation — Employment Agreements.”

Indemnification

We have entered into indemnification agreements with each of our directors and executive officers that provide our directors and executive officers with additional protection regarding the scope of the indemnification set forth in our memorandum and articles of association. Pursuant to these agreements, we indemnify each of our directors and executive officers (to the fullest extent permitted by Cayman Islands law) against all costs and expenses, including expense advances, incurred in connection with any claim by reason or arising out of any event or occurrence relating to the fact that such person is our director or executive officer or is serving at our request at another corporation or entity, or by reason of any activity or inactivity while serving in such capacity. We are not, however, obligated to indemnify any such person:

•        For expenses resulting from matters for which such person is prohibited from being indemnified under our memorandum and articles of association then in effect or applicable laws;

•        In respect of any claim initiated or brought voluntarily by such person (other than in limited specified circumstances); or

•        For expenses incurred in relation to any proceedings to enforce the agreement in which material assertions in such proceedings made by such person are finally determined by a court to be not made in good faith or to be frivolous.

25

Registration rights

We entered into a registration rights agreement with Campus Holdings Limited (“Campus”), Dr. Huang and Spin-Rich Ltd., which entitles them to certain registration rights, including demand registration rights, Form S-3 registration rights, and piggyback registration rights.

For more details of our related party transactions, please see Note 20 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.

Policies and Procedures for Related Persons Transactions

Our Audit Committee has adopted an internal policy regarding the identification, review, consideration and oversight of any transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any “related party” are participants. Transactions involving compensation for services provided to us as an employee, director, consultant or similar capacity by a related person are not covered. A related party is any executive officer, director or a holder of more than five percent of our ordinary shares, including any of their immediate family members and any entity owned or controlled by such persons.

Under our policy, where a transaction has been identified as a related party transaction, management must present information regarding the proposed related party transaction to the Audit Committee of our Board of Directors for review. The presentation must include a description of, among other things, the material facts, the direct and indirect interests of the related parties, the benefits of the transaction to us and whether any alternative transactions are available. To identify related party transactions in advance, we rely on information supplied by our executive officers, directors and certain significant shareholders. In considering related party transactions, the Audit Committee of our Board of Directors takes into account the relevant available facts and circumstances including, but not limited to the risks, costs and benefits to us; the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; the terms of the transaction; the availability of other sources for comparable services or products; and the terms available to or from, as the case may be, unrelated third parties or to or from our employees generally. In the event a director has an interest in the proposed transaction, the director must excuse himself or herself from the deliberations and approval.

Director Independence

The Board has determined that Yigong Justin Chen, Mingjun Wang and Yanhui Ma are “independent” under the current independence standards of NYSE American and meet the criteria set forth in Rule 10A-3 under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”).

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ELECTION OF THE BOARD OF DIRECTORS’ NOMINEES.

PLEASE NOTE: If your shares are held in street name, your broker, bank, custodian, or other nominee holder cannot vote your shares in the election of directors, unless you direct the holder how to vote, by marking your proxy card.

26

PROPOSAL 2

RATIFICATION OF THE APPOINTMENT OF INDEPENDENT ACCOUNTANTS

The Audit Committee has appointed Guangdong Prouden CPAs GP as independent auditor to audit the financial statements of the Company for the year ending December 31, 2026 relating to financial statements prepared in accordance with GAAP, and the Board of Directors is asking shareholders to ratify that appointment.

A representative of Guangdong Prouden CPAs GP is expected to be present at the Annual Meeting, with the opportunity to make a statement, if he or she desires to do so, and is expected to be available to respond to appropriate questions.

The Audit Committee is not required to take any action as a result of the outcome of the vote on this proposal. In the event shareholders fail to ratify the appointment, the Audit Committee will reconsider this appointment. Even if the appointment is ratified, the Audit Committee, in its discretion, may direct the appointment of a different independent accounting firm at any time during the year if the Audit Committee determines that such a change would be in the Company’s and the shareholders’ best interests.

Services and Fees of Independent Accountants

The Audit Committee engaged Guangdong Prouden CPAs GP to perform an annual audit of our financial statements for the fiscal years ended December 31, 2025 and 2024. The following is the breakdown of aggregate fees paid for the last two fiscal years. Another tax firm prepares our tax returns.

 

Year Ended
December 31,
2025

 

Year Ended
December 31,
2024

   

(In million)

Audit fees

 

$

0.2

 

$

0.2

Audit-related fees

 

 

—

 

 

—

Tax fees

 

 

—

 

 

—

All other fees

 

 

—

 

 

—

Total

 

$

0.2

 

$

0.2

“Audit Fees” consist of fees billed for professional services rendered for the audit of our financial statements and services that are normally provided by the above auditors in connection with statutory and regulatory filings or engagements.

“Audit-related fees” consist of assurance and related services that are reasonably related to the performance of audit or review of our financial statements related to our SEC filings.

“Tax Fees” are fees primarily for tax compliance in connection with filing US income tax returns.

“All other fees” consist of fees for services not included in the categories above, including advisory, consulting, and other permissible non-audit services provided by our independent auditors.

Audit Committee Pre-Approval of Services

The Audit Committee has established a pre-approval policy and procedures for audit, audit-related and tax services that can be performed by the independent auditors without specific authorization from the Audit Committee subject to certain restrictions. The policy sets out the specific services pre-approved by the Audit Committee and the applicable limitations, while ensuring the independence of the independent auditors to audit our financial statements is not impaired. The pre-approval policy does not include a delegation to management of the Audit Committee’s responsibilities under the Exchange Act. During the year ended December 31, 2025, the Audit Committee pre-approved all audit and permissible non-audit services provided by our independent auditors.

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR” RATIFICATION OF THE APPOINTMENT OF THE INDEPENDENT ACCOUNTANTS.

27

PROPOSAL 3

ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION

Pursuant to Securities Exchange Act Section 14A, we are submitting to shareholders an advisory vote to approve the compensation paid to the Company’s named executive officers, as disclosed under the caption Executive Compensation, pursuant to Item 402 (m) through (q) of Regulation S-K, compensation tables, and narrative discussion.

The advisory vote is not binding on the Company, the Board of Directors, or management; if executive compensation is not approved by a simple majority of the Class A and Class C ordinary shares (voting together) present and entitled to vote at the Annual Meeting, the Compensation Committee will take account of this fact when considering executive compensation for future years.

The Company is also submitting to shareholders, as Proposal 4, an advisory vote on the frequency of future advisory votes to approve executive compensation.

The affirmative vote of a simple majority of the Class A and Class C ordinary shares (voting together) present and entitled to vote at the Annual Meeting is required for advisory approval of executive compensation.

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR” THE FOLLOWING ADVISORY RESOLUTION:

RESOLVED, that the compensation paid to Company’s named executive officers, as disclosed under the caption Executive Compensation, pursuant to Item 402 (m) through (q) of Regulation S-K, compensation tables, and narrative discussion, be, and hereby is, approved.

PLEASE NOTE: If your shares are held in street name, your broker, bank, custodian, or other nominee holder cannot vote your shares on this proposal, unless you direct the holder how to vote, by marking your proxy card or by following the instructions on the proxy card to vote.

28

PROPOSAL 4

ADVISORY VOTE ON THE FREQUENCY OF
FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION

Pursuant to Section 14A of the Securities Exchange Act of 1934 and Rule 14a-21(b) thereunder, we are asking shareholders to indicate, on an advisory basis, whether future advisory votes to approve the compensation of the Company’s named executive officers, such as Proposal 3, should be held every one, two or three years. Shareholders may also abstain from voting on this proposal.

After careful consideration, the Board of Directors has determined that an advisory vote on executive compensation held every three years is the most appropriate alternative for the Company. In formulating its recommendation, the Board considered that an advisory vote at this frequency will allow shareholders to provide timely, direct input on the Company’s executive compensation philosophy, policies and practices while giving the Compensation Committee sufficient time to evaluate and respond to shareholder input.

Shareholders are not voting to approve or disapprove the Board’s recommendation. The proxy card provides four choices: every one year, every two years, every three years, or abstain. The frequency receiving the greatest number of votes cast will be considered the frequency selected by shareholders. Because this vote is advisory, it is not binding on the Company, the Board of Directors or the Compensation Committee, and the Board may decide that it is in the best interests of the Company and its shareholders to hold advisory votes on executive compensation more or less frequently than the frequency selected by shareholders. The Company will disclose the Board’s decision regarding frequency in a Current Report on Form 8-K.

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR A FREQUENCY OF EVERY THREE YEARS FOR FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.

PLEASE NOTE: If your shares are held in street name, your broker, bank, custodian, or other nominee holder cannot vote your shares on this proposal, unless you direct the holder how to vote, by marking your proxy card or by following the instructions on the proxy card to vote.

29

OTHER INFORMATION

The Company’s 2025 annual report on Form 10-K, excluding exhibits, will be mailed without charge to any shareholder entitled to vote at the meeting, upon written request to Dr. Jin Huang, Chief Executive Officer, Ambow Education Holding Ltd., 10080 N. Wolfe Rd, Suite SW3-200, Cupertino, CA 95014. Proxy materials are also available on the Company website at: www.ambow.com.

Important Notice Regarding Delivery of Shareholder Documents

If your shares are held in street name, your broker, bank, custodian, or other nominee holder may deliver only one copy of this proxy statement and the annual report to shareholders to multiple shareholders sharing an address, absent contrary instructions from one or more of the shareholders. The Company will deliver a separate copy of the proxy materials to a shareholder at a shared address to which a single copy was delivered, upon written or oral request, to Dr. Jin Huang, Chief Executive Officer, Ambow Education Holding Ltd., 10080 N. Wolfe Rd, Suite SW3-200, Cupertino, CA 95014, telephone number (619) 684-8954. Shareholders sharing an address and receiving multiple copies of the proxy materials who wish to receive a single copy should contact their broker, bank, custodian or other nominee holder.

Other Matters to Be Presented at the Annual Meeting

The Company is not aware of any matter to be presented for action at the Annual Meeting, except as discussed in this proxy statement. The persons authorized by the accompanying form of proxy will vote in their discretion as to any other matter that comes before the Annual Meeting.

Shareholder Proposals for Next Annual Meeting

Shareholder proposals intended to be included in the proxy statement for the 2027 annual meeting pursuant to Rule 14a-8 under the Exchange Act must be received by the Company at its principal executive offices no later than July 22, 2027, which is 120 days before the anniversary of the date this proxy statement was first sent to shareholders. If the date of the 2027 annual meeting changes by more than 30 days from the anniversary of this year’s meeting, proposals must be received within a reasonable time before the Company begins to print and send its proxy materials. The 2027 annual meeting is anticipated to occur on or about December 18, 2027.

By Order of the Board of Directors,

   

/s/ Jin Huang

   

Jin Huang

   

Chairwoman of the Board

   

30

ANNUAL MEETING OF SHAREHOLDERS OF

AMBOW EDUCATION HOLDING LTD.

DECEMBER 18, 2026

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 18, 2026:

The Notice of Annual Meeting of Shareholders, Proxy Statement, form of Proxy Card and Annual Report
to Shareholders are available free of charge at https://www.ambow.com. To reduce costs and environmental impact, shareholders may elect to receive future proxy materials electronically by contacting their broker, bank or other nominee. An election to receive materials electronically will remain in effect until revoked.

Please sign, date and mail your proxy card in the envelope provided promptly.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ELECTION OF THE CLASS III DIRECTORS, “FOR” PROPOSAL 2, “FOR” PROPOSAL 3, and “FOR” A FREQUENCY OF EVERY THREE YEARS ON PROPOSAL 4. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE ¨

This Proxy is Solicited on Behalf of the Board of Directors

The undersigned hereby appoints Jin Huang, individually, as proxy to represent the undersigned at the Annual Meeting of Shareholders to be held at 10:00 a.m. Pacific Time, at 1249 F St, San Diego, CA 92101, and at any adjournments thereof, and to vote the ordinary shares the undersigned would be entitled to vote if personally present, as indicated below.

1.

 

ELECTION OF DIRECTORS:

 

NOMINEES:

☐

 

‥

 

FOR ALL NOMINEES

 

Jin Huang and Yanhui Ma

☐

 

‥

 

AGAINST ALL NOMINEES

   

☐

 

‥

 

FOR ALL EXCEPT (See instructions below)

INSTRUCTIONS: To withhold authority to vote for any individual nominee(s), mark “FOR ALL EXCEPT” and write the name(s) of the nominee(s) you wish to withhold on the line below:

2.

 

RATIFICATION OF INDEPENDENT AUDITOR

☐

 

‥

 

FOR

☐

 

‥

 

AGAINST

☐

 

‥

 

ABSTAIN

3.

 

ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION

☐

 

‥

 

FOR

☐

 

‥

 

AGAINST

☐

 

‥

 

ABSTAIN

4.

 

ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION

☐ 1 YEAR

 

☐ 2 YEARS

 

☐ 3 YEARS

 

☐ ABSTAIN

 

If any other business is presented at the meeting, this proxy will be voted by those named in this proxy in their best judgment. At the present time, the Board of Directors knows of no other business to be presented at the meeting. The ordinary shares represented by this proxy, when properly executed, will be voted as directed. If no direction is given, this proxy will be voted “FOR” Items 1, 2 and 3 and for a frequency of every “3 YEARS” on Item 4. Holders of the Company’s American depositary shares (“ADS”) who wish to exercise their voting rights for their underlying ordinary shares must act through the depositary of the Company, Citibank, N.A. We encourage you to provide instructions to Citibank, N.A. if you hold ADS.

Signature of Shareholder

 

 

 

Date

 

 

Signature of Shareholder

 

 

 

Date

 

 

Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.

 

Keep reading